Synovis Life Technologies, Inc.
Synovis Life Technologies adopts new shareholder rights plan
Published in Medicine and Law Weekly, June 30th, 2006
The purpose of the new agreement is to protect the company and its shareholders from unsolicited attempts or inequitable offers to acquire the company. The rights agreement has no immediate dilutive effect and does not diminish the ability of Synovis or its shareholders to accept a fair offer to acquire the company in a negotiated transaction.
To implement this shareholder rights agreement, the company has declared a distribution of one common share purchase right on...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- American Association for the Study of Liver Diseases
Education and guidelines needed for genetic testing in liver disease - Antares Pharma, Inc.
Antares Pharma, Eli Lilly file joint patent application for needle-free injection device - Avid Radiopharmaceuticals, Inc.
Avid Radiopharmaceuticals adds three industry veterans - BioProgress plc
BioProgress subsidiary files patent application for use of XGEL film system - BioTechnology GmbH
BioTechnology reports basis patent for Sloning gene synthesis technology was granted - Boston Scientific Corporation
Court of Appeals rules Boston Scientific's products do not infringe Medtronic stent patents - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
